General Information of Drug (ID: DMR5ATX)

Drug Name
NKR-2 cells Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMR5ATX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NN8555 DM3IEHP Crohn disease DD70 Phase 2 [2]
NKR-2 CAR-T Cells DMDLJM1 Acute myeloid leukaemia 2A60 Phase 1 [3]
CYAD-101 DMSM42V Colorectal cancer 2B91.Z Phase 1 [4]
CM-CS1 T-cell DMY5V4U Acute myeloid leukaemia 2A60 Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
NKG2 D activating NK receptor (KLRK1) TTLRN4A NKG2D_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
4 ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
5 ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands